Method for predicting of sensitivity to chemotherapy for colorectal cancer

Capable of selecting anti EGFR antibody-sensitive/resistant patient from Ras wild-type group

Abstract

Anti-EGFR treatment for colorectal cancer is effective for patients without RAS mutation. However, response rate of the treatment is no more than 30%. This inventor analyzed the DNA methylation status of tissue samples from patients treated by anti-EGFR antibody.
The result showed that highly methylated colorectal cancer (HMCC) has higher drug resistance than low methylated colorectal cancer (LMCC).

Effect & Application

• Progression-free survival of HMCC is shorter than LMCC on cohort A and B.
• Progression-free survival and overall survival of HMCC is similar to RAS mutant.
→This invention makes it possible to avoid side effects and unnecessary drug administration in the drug-resistant patients, and to predict sensitivity to chemotherapy independently of cancer stage or sample condition.

Patent Information

IP No.　 ： Publication No. WO2016/060278
Inventor ： ISHIOKA Chikashi, TAKAHASHI Shin, OUCHI
keyword ： Medical drug(including research tools)